Keyphrases
ErbB2
100%
FOLFIRINOX
100%
Advanced Gastroesophageal Cancer
100%
Non-randomized Clinical Trial
100%
Objective Response Rate
62%
Gastroesophageal Adenocarcinoma
50%
Trastuzumab
37%
Progression-free Survival
25%
Median Overall Survival
25%
Median Progression-free Survival
25%
Toxic Effects
25%
Oxaliplatin
25%
Irinotecan
25%
Leucovorin
25%
Fluorouracil
25%
First-line Regimen
25%
Performance Status
12%
Diarrhea
12%
Neutropenia
12%
Nausea
12%
Overall Survival
12%
Safety Profile
12%
Pancreatic Cancer
12%
Trial Registration
12%
Phase II Study
12%
First-line Therapy
12%
Treatment Delay
12%
Complete Response
12%
Therapeutic Potential
12%
Starting Dose
12%
Positive Groups
12%
Colon Cancer
12%
Duration of Response
12%
Bolus
12%
Dose Adjustment
12%
Response Evaluation Criteria in Solid Tumors (RECIST)
12%
Gastrointestinal Cancer
12%
Clinical Safety
12%
Clinical Activity
12%
Median Range
12%
Peripheral Sensory Neuropathy
12%
Loading Dose
12%
FOLFOX Regimen
12%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Progression Free Survival
100%
Adenocarcinoma
100%
Overall Survival
75%
Trastuzumab
75%
Diseases
75%
Irinotecan
50%
Oxaliplatin
50%
Folinic Acid
50%
Fluorouracil
50%
Diarrhea
25%
Neutropenia
25%
Nausea
25%
Solid Malignant Neoplasm
25%
Colon Carcinoma
25%
Sensory Neuropathy
25%
Digestive System Cancer
25%